marcus evans europe conferences

9th Annual Biologics Formulation Development and Drug Delivery Forum

Foster the Robustness of your Formulation Through all the Processes to Ensure a Safe Delivery to Patient

6-8 June 2018
Amsterdam, Netherlands


Why You Should Attend

9th Annual Biologics Formulation Development and Drug Delivery Forum

This marcus evans forum will feature these existing key problems confronting formulation scientists and assist them with a better experiment protocol to ensure quality processes aligned with health authorities requirements, robust and rational methodology to minimise failure risks. The delegates will benefit from experienced case study and understand how to improve formulation stability, preventing aggregation, develop high-concentration forms; they will also learn how to use predictive and analytical methods in order to understand the behaviour and evolution of proteins under different stresses and help scientists characterising proteins and different components of the formulation. They will also apprehend the manufacturing and scale up challenges, looking at compatibility problems, lyophilisation issues, and consider the different possibilities offered for drug delivery, keeping in mind the crucial need for improving comfort and safety to patient.

Optimising biologic therapeutic products with increasing complex molecules have become a highly important area for the pharmaceutical industry. Formulation scientists still face large challenges in getting a stable, potent and safe product, mainly considering aggregation concerns, particle detection, bioavailability and immunogenicity.  On the whole process also, formulation scientists need to get a clearer view from formulation phase up to manufacturing and drug delivery, as influence of final result impact largely the way formulation is developed.


Key Topics

  • Improve the design of biological formulation with automated and high-throughput solutions
  • Integrate QbD processes in biological drug development
  • Enhance stability process controlling aggregation
  • Improve characterization with efficient analytical tools
  • Discuss the regulatory environment around biological drug development
  • Previous Attendees Include

    • GlaxoSmithKline
    • Pfizer
    • Abbvie
    • Roche Biologics
    • UCB
    • Sandoz
    • Abbott
    • Baxter
    • Novartis Vaccines
    • Sanofi aventis
    • Boehringer Ingelheim
    • Medimmune
    • Bayer
    • Bristol-Myers Squibb
    • Genentech
    • Janssen Pharmaceutical
    • Merck & Co
    • Novo Nordisk
    • University of Cambridge


    Why Choose marcus evans?

    marcus evans specialises in the research and development of strategic events for senior business executives. From our international network of 63 offices, marcus evans produces over 1000 event days a year on strategic issues in corporate finance, telecommunications, technology, health, transportation, capital markets, human resources and business improvement.

    Above all, marcus evans provides clients with business information and knowledge which enables them to sustain a valuable competitive advantage and makes a positive contribution to their success.







    Voice of Our Customers
    • “The conference was very interesting – all the topics presented have been very useful!”, Genzyme
    • “Really enjoyed the speakers & interactivity of the event!”, Ipsen
    • “One of the best meetings I’ve attended. Excellent organisation, topics and speakers”, GSK
    • “High quality agenda and fantastic speakers, I would definitely attend again”, Roche
    Latest Conference News & Resources



    Join the Discussion

    Follow on LinkedIn





    Event Contact

    For all enquiries regarding speaking, sponsoring and attending this conference contact:

    Constandinos Vinall


    marcus evans (Europe) Ltd
    PO Box 24797
    1304 Nicosia, Cyprus

    Telephone:
    +357 22849 380
    Fax: +357 22849 394
    Email: constandinosv@marcusevanscy.com